Navigation Links
NIAID DNA vaccine for H5N1 avian influenza enters human trial

The first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began on December 21, 2006, when the vaccine was administered to the first volunteer at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. Scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the NIH Institutes, designed the vaccine. The vaccine does not contain any infectious material from the influenza virus.

Unlike conventional flu vaccines, which are developed by growing the influenza virus in hens' eggs and then administered as a weakened or killed form of the virus, DNA-based vaccines contain only portions of the influenza virus' genetic material. Once inside the body, the DNA instructs human cells to make proteins that act as a vaccine against the virus.

VRC Director Gary Nabel, M.D., Ph.D., together with a team of scientists from the VRC recognized the potential for employing new vaccine technology against influenza, a disease for which effective vaccines have long been made, but for which the reliability of supply and manufacturing capacity has been problematic. Dr. Nabel and his colleagues previously have shown the DNA vaccine approach to be effective against influenza viruses in animal models, including highly pathogenic viruses such as the H5N1 strain and the H1N1 virus that caused the deadly 1918 pandemic. The DNA vaccine used in this study is similar to other investigational vaccines evaluated by the VRC that hold promise for controlling other viruses, such as HIV, Ebola, SARS and West Nile.

"An effective H5N1 influenza vaccine would provide a potentially life-saving advance against a global health threat," notes NIAID Director Anthony S. Fauci, M.D. "More broadly, development of this DNA vaccine technology has the potential to improve our production capacity for vaccines to prevent seasonal influenza and other diseases."

"This i
'"/>

Source:NIH/National Institute of Allergy and Infectious Diseases


Page: 1 2 3

Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. NIAID begins clinical trial of West Nile virus vaccine
3. New NIAID grants strengthen national biodefense and emerging infectious diseases research network
4. NIAID researchers show how promising TB drug works
5. NIAID expands capability for influenza research and surveillance
6. Research advances quest for HIV-1 vaccine
7. A much-needed shot in the arm for HIV vaccine development
8. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
9. Gene vaccine for Alzheimers disease shows promising results
10. Influenza vaccine uses insect cells to speed development
11. Norovirus, AIDS vaccine and Hepatitis Virus

Post Your Comments:
(Date:11/25/2009)...e heart pumps some 250 million liters of blood thr... fibers of the heart have to be extremely durable....er, vice chair of the Department of Medicine III a...Dr. H. A. Katus), has discovered a protein that is...cular unit, the sarcomere. In cooperation with oth...
(Date:11/25/2009)... just as vital to your health as what you eat, fou...l Studies. Their experiments in mice revealed that... in the liverthe body,s metabolic clearinghouseis ...dy,s circadian clock as conventional wisdom had it... a large number of genes completely independent of...
(Date:11/24/2009)...) today named 12 new grant recipients for 2009. Th...ive work across a broad spectrum of lupus research... and potential to drive scientific discovery to ul...ase of systemic lupus. , The 2009 grants go to b...he nation and include interdisciplinary and highly...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Feeding the clock 2Feeding the clock 3Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Tyco International to Present at the Citi Industrial Manufacturing 26amp 3B Transportation Conference 60962 1Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 1Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 14768 3Pharma and Biotech Leaders to Converge in Shanghai 14765 1Pharma and Biotech Leaders to Converge in Shanghai 14765 2
...ow highlight research in the ESA journals Frontie...ological Applications and Ecological Monographs ... wildfire severity but may invite invasives , ...compares the effectiveness of fire fuel reduction ...ogate Study. Four articles examine the effects of ...
.... Prenatal exposure to an insecticide commonly us...ty epidemic in women, according to a new study inv...rs. , More than 250 mothers who live along and ea...xposure to DDE a breakdown of DDT. The study, pub...on of Occupational and Environmental Medicine , a...
...as a moon named Deimos, so it seems only appropria... have its own DEIMOS. This DEIMOS, however, is an ...vements of fish and zooplankton. , MARS, which st...sists of a node the size of two compact cars that ...rnet connection for scientific instruments. Connec...
Other Biology News:Highlights from the March editions of ESA journals 2Highlights from the March editions of ESA journals 3Exposure to insecticide may play role in obesity epidemic among some women 2DEIMOS joins MARS and its satellite of instruments on seafloor 2DEIMOS joins MARS and its satellite of instruments on seafloor 3
(Date:11/24/2009)...EN,Italy,November24/PRNewswire/--HealthRoboticstod...ewithagroupofselected,investors.Thisrecentlyformed...RoboticsCanada,Inc.andwillmarket,install,andsuppor...ncludesthe,revolutionaryproductofferingsi.v.STATIO...aInc.willalsoprovideassistanceonan"asneeded,basis"...
(Date:11/24/2009)...TTLE,Nov.24/PRNewswire-FirstCall/--CellTherapeutic...tatthe21stAnnualPiperJaffrayHealthCareConference.T...kPalaceHotel. ,, CTIwillpresentonTuesday,Decemb...audiowebcastofCTI,spresentationwillbeavailableat w...orreplayafterwards. , ,PiperJaffrayHealthCareConf...
(Date:11/23/2009)...omputing promises ultra-fast communication, comput...information. But trying to use quantum states as c...siness. Now two physicists have shown, mathematica...ntum communication, while keeping the information ...e of Physical Review Letters and highlighted wit...
(Date:11/23/2009)...SISSAUGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioScie...ctdevelopmentcompanythatidentifiesandadvancesadive...iousstagesofdevelopment,todayreportedthatCytopia(A...uatingCYT387,apotent,orally-administeredJAK1/JAK2i...hester,Minnesota.AproposaltomergeCytopiaintoYMhasb...
Breaking Biology Technology:Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...e profiling of protein biomarkers in tissue now, ...utions through Brigham and Women,... 29 HistoRx, Inc., announced today,that the patho... (BWH) will,begin making the company,s AQUA(R) tec...to the more than 900 Dana-Farber/Harvard Cancer Ce...
...atic, or fully differentiated, human cells back to...any of the significant scientific and social chall...help realize the promise of regenerative medicine....monstrated that such a transformation (reprogrammi...nefficient and, when it does work, poorly understo...
..., Inc. (Nasdaq:,SQNM) today announced that a live ...will be provided for its analyst and investor brie...enatal Diagnostics." Details of the,event are as f...nvasive Prenatal Diagnostics, When: Tuesday, ... http://www.sequenom.com , Agenda: Hosted by:...
Other Biology Technology:HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center 2HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center 3New insights into cellular reprogramming revealed by genomic analysis 2Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3 2
QuantiChrom Zinc Assay Kit from BioAssay Systems
Mouse Anti-Human PDGF R beta Monoclonal Antibody, Unconjugated, Clone PR7212 from R&D Systems
Mouse IL-23, Unconjugated from R&D Systems
Rabbit Serum from Lifeblood Medical, Inc.
Biology Products: